Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia

Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311

Vrablík, 2001, Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis, Physiol. Res., 50, 337

Soutar, 2007, Mechanisms of disease: genetic causes of familial hypercholesterolemia, Nat. Clin. Pract. Cardiovasc. Med., 4, 214, 10.1038/ncpcardio0836

Medeiros, 2010, Update of the Portuguese Familial Hypercholesterolaemia Study, Atherosclerosis, 212, 553, 10.1016/j.atherosclerosis.2010.07.012

Usifo, 2012, Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment, Ann. Hum. Genet., 76, 387, 10.1111/j.1469-1809.2012.00724.x

Soutar, 2010, Rare genetic causes of autosomal dominant or recessive hypercholesterolaemia, IUBMB Life, 62, 125, 10.1002/iub.299

Miserez, 1995, Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol, 15, 1719, 10.1161/01.ATV.15.10.1719

März, 1993, Accumulation of “small dense” low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor, J. Clin. Invest., 92, 2922, 10.1172/JCI116915

Innerarity, 1987, Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding, Proc. Natl. Acad. Sci. USA, 84, 6919, 10.1073/pnas.84.19.6919

Chatterton, 1995, Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering, Biochemistry, 34, 9571, 10.1021/bi00029a034

Boren, 2001, The molecular mechanism for the genetic disorder familial defective apolipoprotein B100, J. Biol. Chem., 276, 9214, 10.1074/jbc.M008890200

Krisko, 2007, Theoretical model of human apolipoprotein B100 tertiary structure, Proteins, 66, 342, 10.1002/prot.21229

Prassl, 2009, Molecular structure of low density lipoprotein: current status and future challenges, Eur. Biophys. J., 38, 145, 10.1007/s00249-008-0368-y

Myant, 1993, Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia, Atherosclerosis, 104, 1, 10.1016/0021-9150(93)90171-P

Meng, 1996, Analysis of novel apolipoprotein B mutations using a modified U937 cell line LDL binding assay, Clin. Chim. Acta, 256, 27, 10.1016/S0009-8981(96)06409-1

Pullinger, 1999, The apolipoprotein B R3531C mutation. Characteristics of 24 subjects from 9 kindreds, J. Lipid Res., 40, 318, 10.1016/S0022-2275(20)33372-1

Gaffney, 1995, Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia, Arterioscler. Thromb. Vasc. Biol., 15, 1025, 10.1161/01.ATV.15.8.1025

Motazacker, 2012, Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia, Eur. Heart J., 33, 1360, 10.1093/eurheartj/ehs010

Abecasis, 2010, A map of human genome variation from population-scale sequencing, Nature, 467, 1061, 10.1038/nature09534

Bourbon, 2008, Familial hypercholesterolaemia in Portugal, Atherosclerosis, 196, 633, 10.1016/j.atherosclerosis.2007.07.019

Marks, 2003, A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia, Atherosclerosis, 168, 1, 10.1016/S0021-9150(02)00330-1

Kusters, 2011, Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes, Neth. Heart J., 19, 175, 10.1007/s12471-011-0076-6

Futema, 2012, Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia, J. Med. Genet., 49, 644, 10.1136/jmedgenet-2012-101189

Talmud, 2013, Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study, Lancet, 381, 1293, 10.1016/S0140-6736(12)62127-8

Fouchier, 2005, Update of the molecular basis of familial hypercholesterolemia in The Netherlands, Hum. Mutat., 26, 550, 10.1002/humu.20256

Abifadel, 2012, Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia, Atherosclerosis, 223, 394, 10.1016/j.atherosclerosis.2012.04.006

Hooper, 2012, Genetic analysis of familial hypercholesterolaemia in Western Australia, Atherosclerosis, 224, 430, 10.1016/j.atherosclerosis.2012.07.030

Bertolini, 2013, Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy, Atherosclerosis, 227, 342, 10.1016/j.atherosclerosis.2013.01.007

Futema, 2013, Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic, Atherosclerosis, 10.1016/j.atherosclerosis.2013.04.011

Lank, 2010, A novel single cDNA amplicon pyrosequencing method for high-throughput, cost-effective sequence-based HLA class I genotyping, Hum. Immunol., 71, 1011, 10.1016/j.humimm.2010.07.012

Michils, 2012, Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing, J. Mol. Diagn., 14, 623, 10.1016/j.jmoldx.2012.05.006

Frostegård, 1990, Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein, J. Lipid Res., 31, 37, 10.1016/S0022-2275(20)42758-0

Van den Broek, 1994, Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay, Clin. Chem., 40, 395, 10.1093/clinchem/40.3.395

Nigon, 1991, Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor, J. Lipid Res., 32, 1741, 10.1016/S0022-2275(20)41629-3

Mahley, 1977, Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins, J. Biol. Chem., 252, 7279, 10.1016/S0021-9258(19)66966-8

Weisgraber, 1978, Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts, J. Biol. Chem., 253, 9053, 10.1016/S0021-9258(17)34284-9

Mahley, 1979, Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors, Biochim. Biophys. Acta, 575, 81, 10.1016/0005-2760(79)90133-4

Brouwers, 2012, The genetics of familial combined hyperlipidaemia, Nat. Rev. Endocrinol., 8, 352, 10.1038/nrendo.2012.15

Buch, 2007, A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease, Nat. Genet., 39, 995, 10.1038/ng2101

Chen, 2008, Significant association of ABCG8:D19H gene polymorphism with hypercholesterolemia and insulin resistance, J. Hum. Genet., 53, 757, 10.1007/s10038-008-0310-2

Srivastava, 2010, Role of ABCG8 D19H (rs11887534) variant in gallstone susceptibility in northern India, J. Gastroenterol. Hepatol., 25, 1758, 10.1111/j.1440-1746.2010.06349.x

Den Dunnen, 2000, Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion, Hum. Mutat., 15, 7, 10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N

Adzhubei, 2010, A method and server for predicting damaging missense mutations, Nat. Methods, 7, 248, 10.1038/nmeth0410-248

Ng, 2003, SIFT: predicting amino acid changes that affect protein function, Nucleic Acids Res., 31, 3812, 10.1093/nar/gkg509

González-Pérez, 2011, Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel, Am. J. Hum. Genet., 88, 440, 10.1016/j.ajhg.2011.03.004

Schwarz, 2010, MutationTaster evaluates disease-causing potential of sequence alterations, Nat. Methods, 7, 575, 10.1038/nmeth0810-575

Grantham, 1974, Amino acid difference formula to help explain protein evolution, Science, 185, 862, 10.1126/science.185.4154.862

Etxebarria, 2012, Functional characterization of splicing and ligand-binding domain variants in the LDL receptor, Hum. Mutat., 33, 232, 10.1002/humu.21630

Catapano, 2011, ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis, 217, 3, 10.1016/j.atherosclerosis.2011.06.028

Marduel, 2013, Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation, Hum. Mutat., 34, 83, 10.1002/humu.22215

Pollin, 2008, A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection, Science, 322, 1702, 10.1126/science.1161524